Post-Transplant Use of Renin-Angiotensin Inhibitors and Chronic Lung Allograft Dysfunction (CLAD)
Purpose: CLAD remains the main limitation to long-term survival after lung transplant and there is no effective therapy or prevention. CLAD is characterized by small airway fibrosis and different degrees of parenchymal fibrosis depending on phenotype. The renin-angiotensin system has been incriminated in fibrosis in different organs. We hypothesized that inhibiting the RA system would decrease subsequent CLAD development. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , S. Wang, L. Levy, M. Kawashima, B. Renaud-Picard, R. Ghany, S. Farkona, S. Keshavjee, M. Aversa, L. Singer, A. Konvalinka, J. Tikkanen, E. Huszti, T. Martinu Source Type: research
Ten Years Since Photopheresis. Have We Change our Clinical Practice?
Purpose: To evaluate our experience after 10 years of extracorporeal photopheresis (ECP) in lung transplant patients with Chronic Lung Allograft Disfunction (CLAD). (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , R. Laporta Hernandez, J. Bueno Cabrera, C. Garcia Fadul, M. Erro Iribarren, M. Lazaro Carrasco de la Fuente, C. Almonacid Sanchez, P. Ussetti Gil Source Type: research
Evaluation of Use of Tacrolimus vs. Cyclosporine on CLAD Incidence and Allograft Survival in the ISHLT Registry
Purpose: The ScanCLAD study reported a lower incidence of CLAD with the use of once daily tacrolimus vs. twice daily cyclosporine. Using the ISHLT Registry data, we evaluated the hypothesis that tacrolimus would be superior to cyclosporine with regards to CLAD development in real world clinical practice. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , K. Walter, H. Hixson, E.A. Belloli, K.M. Chan, A.C. Chang, D.M. Lyu Source Type: research
Bronchoalveolar Lavage and Plasma Proteomes Identify Features of Disease That Segregate Lung Transplant Recipients with versus without Bronchiolitis Obliterans Syndrome
Purpose: Protein biomarkers of chronic lung allograft dysfunction (CLAD) can aid in early detection before clinical diagnosis and may shed light on the molecular underpinnings of disease. We hypothesized that determining proteomic differences in the bronchoalveolar lavage fluid (BALF) of LTx recipients with CLAD-bronchiolitis obliterans syndrome (BOS) phenotype versus no CLAD-BOS can identify disease-associated biomarkers and pathways and suggest therapeutic interventions. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , M.E. Siefert, A.S. Potter, N. Sharma, D. Hayes, A.G. Ziady Source Type: research
Longitudinal Increases in Bronchoalveolar Lavage Interleukin-6, Interleukin-8, Macrophage Inflammatory Protein-1a, and Transforming Growth Factor ß Predict Progressive Chronic Lung Allograft Dysfunction
Purpose: Participants in the ASSIST CLAD study of mesenchymal stromal cell therapy in new-onset chronic lung allograft dysfunction (CLAD) participated in an optional bronchoalveolar lavage (BAL) sub-study, providing an opportunity to investigate relationships between longitudinal change in BAL biomarkers and subsequent CLAD outcome. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: B. O'Sullivan, M. Tan, S.H. Apte, T. de Silva, P. Groves, V.P. Lutzky, G. Westall, D. Darley, M. Musk, A. Glanville, M. Malouf, C. Holmes-Liew, M. Sturm, S. Lawrence, D. Bushell, L. Holsworth, N. Lawson, L. Singleton, S. Timmins, D. Enever, H. Wildermuth, Source Type: research
Exosomal Microrna-17-5p and Microrna-150-5p in Plasma as Diagnostic Markers of Chronic Lung Allograft Dysfunction After Lung Transplantation
Purpose: Circulating microRNAs (miRNAs) have been shown to be potential biomarkers for chronic lung allograft dysfunction (CLAD) after lung transplantation (LT). However, circulating miRNAs consist of miRNAs contained within apoptotic bodies which are released during cell death, protein- or lipid-mediated miRNAs, and exosomal miRNAs (exo-miRNAs) which are actively secreted by living cells. Although exo-miRNAs are involved in the pathogenesis of various diseases, little information has been available about the role of exo-miRNAs in the development of CLAD after LT. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , S. Sugimoto, H. Choshi, S. Tanaka, K. Miyoshi, T. Hayashi, M. Umeda, T. Ryuko, H. Ujike, Y. Kubo, K. Hashimoto, K. Shien, K. Suzawa, H. Yamamoto, M. Okazaki, S. Toyooka Source Type: research
Extracorporeal Photopheresis for CLAD: The Relationship Between Cycle Modification and Response
We describe our experience with 1.5 ECP vs 2 ECP in patients under chronic maintenance for CLAD at our Center. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , K. Mucaj, D.F. Briganti, C. Mortellaro, C. Perotti, C. Klersy, F. Meloni, C. Del Fante Source Type: research
Long-Term Maintenance of Pulmonary Function in the Contralateral Unaffected Lung with Chronic Lung Allograft Dysfunction After Bilateral Living-Donor Lobar Lung Transplantation
Purpose: Chronic lung allograft dysfunction (CLAD) is a major obstacle to long-term survival after lung transplantation (LT). Compared with cadaveric LT, CLAD after bilateral living-donor lobar lung transplantation (LDLLT) is characterized by a delayed disease onset and development predominantly in the unilateral lung. However, long-term changes in pulmonary function after LDLLT remain unclear. The purpose of this study is to assess the long-term changes in pulmonary function of the affected and unaffected lungs with CLAD after bilateral LDLLT. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , S. Sugimoto, T. Hayashi, T. Ryuko, H. Ujike, S. Kawana, Y. Kubo, S. Tanaka, H. Choshi, M. Ishihara, K. Hashimoto, K. Miyoshi, M. Okazaki, S. Toyooka Source Type: research
Dynamic Contrast-Enhanced MRI in Lung Transplantation Recipients with and without CLAD
Purpose: Chronic lung allograft dysfunction (CLAD) accounts for 20-30% of post-transplantation deaths beyond the first year. The development of non-invasive diagnostic tests for CLAD is an unmet need. Our group has utilized dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in patients with idiopathic pulmonary fibrosis and other lung diseases, to detect changes reflective of the microvasculature and the extravascular extracellular space. The purpose of this longitudinal observation study is to use DCE-MRI to detect functional changes in CLAD not otherwise obtainable. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , A. Susnjar, M. Allison, Y.I. Zhou, S. Montesi Source Type: research
CD40 Ligand and NKG7 Mark Distinct Alloeffector CD4 T Cell Populations in Acute Lung Rejection
Purpose: Lung transplantation remains the only therapeutic option for select patients with end-stage lung diseases. Acute cellular rejection (ACR) is the major risk factor for chronic lung allograft dysfunction (CLAD), the predominant barrier for long-term survival in lung transplant recipients (LTRs). However, little is known about the role of donor specific CD4+T cell responses in ACR and the potential impact on the development of CLAD in LTRs. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , M. Snyder, S. Lieber, K. Devonshire, C. Iasella, M. Sciullo, S. Hannan, R. Koshy, R. Burke, J. Sembrat, J. Pilewski, C. Hage, P. Sanchez, K. Chen, J. McDyer Source Type: research
Developing a Multidimensional Immunological Toolset to Facilitate Rejection Diagnosis and Mechanistic Understanding of Chronic Lung Allograft Dysfunction After Human Lung Transplantation
Purpose: Rejection and infection are risk factors for chronic lung allograft dysfunction (CLAD) that limit lung transplantation (LuTx) success. Despite the importance of T cells in driving alloresponses and immune defense, the dynamic repopulation, clonal distribution, alloreactivity, and anti-microbial reactivity of T cells after LuTx are largely unknown. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , W. Jiao, K.D. Long, T. Young, C. Bay Muntnich, A. Prada Rey, K. Rogers, A. Valena, J. Costa, L. Benvenuto, J. Sonett, P. Lemaitre, F. D ’Ovidio, S. Arcasoy Source Type: research
Intermediate Term Clinical Outcomes Using Donor Derived Cell-Free DNA Testing After Lung Transplantation
Purpose: Characterize the intermediate term clinical outcomes using donor derived cell-free DNA (ddcfDNA) testing and assess associations with donor specific antibody (DSA), culture (CX), acute cellular rejection (ACR), and chronic lung allograft dysfunction (CLAD), incidence after Lung Transplantation (LT). (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , C.R. Ensor, A.M. Ramirez Source Type: research
Lung Transplant Recipients Have High Secretory Phospholipase A2 Levels in the Alveoli: First Insight into a Possible Silent Inflammatory Pattern
Purpose: Survival after lung transplantation is limited by the development of chronic lung allograft dysfunction (CLAD). Inflammation is a driving force in the process leading to CLAD and one of CLAD main features. Several lung inflammatory diseases, including acute lung injury, acute respiratory distress syndrome, asthma, and meconium aspiration syndrome show an increased level of the secretory phospholipase A2 type IIA (sPLA2-IIA) enzyme. sPLA2 is mainly expressed following inflammatory or bacterial stimuli and hydrolyzes membrane and surfactant phospholipids, causing lipidome alteration and the production of arachidonic...
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , C. Camillo, L. Benvenuto, F. D'Ovidio Source Type: research
Dissection of the Role of B Cells in a Murine Model of Ischemia-Reperfusion Injury-Augmented Lung Allograft Chronic Rejection
Purpose: Chronic rejection (CR) and allograft fibrosis limit lung transplant outcomes. Current T cell-focused immunosuppression fails to prevent CR, suggesting that other immune cells play a role. Mature B cells, which include innate-like B1 cells and follicular B2 cells, produce antibodies and subserve other functions. We previously showed that CD20 antibody-mediated B cell depletion of recipients prior to and after transplantation attenuated rejection and fibrosis in a minor alloantigen-mismatched orthotopic lung transplant (OLT) model with prolonged ischemia. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , J. Oliver, T. Watanabe, F. Cui, J. Allen, S. Keshavjee, T. Martinu, S. Juvet Source Type: research
Ex-Vivo Model of EMT: Efficacy of MVs from Bone Marrow Mesenchymal Stromal Cells
Purpose: Chronic Lung Allograft Dysfunction, is represented by progressive airway/interstitial fibrosis thought to be initiated by a process of epithelial-endothelial mesenchymal transition (EMT) which brings to myofibroblast differentiation and proliferation and extracellular matrix deposition. Recent reports have shown that microvescicles (MVs) derived from mesenchymal stem cells (MSCs) can reverse lung inflammation and resulting fibrosis. Among MVs, those obtained from bone marrow mesenchymal stromal cells (BMVs) seem to be active and enriched for anti-inflammatory factors. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: C. Bagnera, S. Bozzini, E. Bozza, P. Comoli, M. Avanzini, S. Croce, G. Baietto, G. Melloni, Source Type: research
